2022 was a shaky year for M&A deals in the pharmaceutical and life sciences sector, as PwC recently surmised. That’s not surprising, given the recession fears and inflation themes common throughout the year. That said, Amgen (Nasdaq:AMGN) and Pfizer bucked the trend by spending 11-figure sums on M&A deals. Bristol Myers Squibb, Biocon Biologics and GSK…